The present invention relates to novel pharmaceutical agents and the process of preparation thereof. The present invention discloses compounds of general formula I, and the process of their preparation. The compounds of the invention are useful in the treatment and prevention of diseases related to cellular stress mediated immune deregulation and loss of homeostasis also including autoimmune diseases, cancers, metabolic, dermatological, cardiovascular and neurodegenerative diseases. ##STR00001##

The present invention relates to novel pharmaceutical agents and the process of preparation thereof. The present invention discloses compounds of general formula I, and the process of their preparation. The compounds of the invention are useful in the treatment and prevention of diseases related to cellular stress mediated immune deregulation and loss of homeostasis also including autoimmune diseases, cancers, metabolic, dermatological, cardiovascular and neurodegenerative diseases. ##STR00001##

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to novel pharmaceutical agents and the process of preparation thereof. The present invention discloses compounds of general formula I, and the process of their preparation. The compounds of the invention are useful in the treatment and prevention of diseases related to cellular stress mediated immune deregulation and loss of homeostasis also including autoimmune diseases, cancers, metabolic, dermatological, cardiovascular and neurodegenerative diseases.

##STR00001##

The present invention relates to novel pharmaceutical agents and the process of preparation thereof. The present invention discloses compounds of general formula I, and the process of their preparation. The compounds of the invention are useful in the treatment and prevention of diseases related to cellular stress mediated immune deregulation and loss of homeostasis also including autoimmune diseases, cancers, metabolic, dermatological, cardiovascular and neurodegenerative diseases.

##STR00001##

The present disclosure relates to an ionic liquid (IL)-based formulation comprising inhibitors of NADPH oxidases enzymes (Nox's), preferably isoforms 1 and 4, in particular the specific inhibitor 3-cyclohexyl-5-(2,4-dihydroxybenzylidene)-1-methyl-2-thiohydantoin, for the treatment, therapy or prevention of neurological diseases, in particular Parkinson's diseases.

The present disclosure relates to an ionic liquid (IL)-based formulation comprising inhibitors of NADPH oxidases enzymes (Nox's), preferably isoforms 1 and 4, in particular the specific inhibitor 3-cyclohexyl-5-(2,4-dihydroxybenzylidene)-1-methyl-2-thiohydantoin, for the treatment, therapy or prevention of neurological diseases, in particular Parkinson's diseases.